annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 31B The National Lung Cancer Audit in the United Kingdom: Results after 4 years.
(Abstract #6123)
P. Beckett, I. Woolhouse, R. Stanley, M. D. Peake
Brd. 31C Education level as prognostic factor of patients (pts) with advanced nonsmall
cell lung cancer (NSCLC) enrolled in clinical trials. (Abstract #6124)
M. Di Maio, A. Morabito, S. Barbera, V. Gebbia, B. Daniele, A. Ceribelli,
F. Carrozza, A. Rossi, S. Signoriello, C. Gridelli
Brd. 32A Relationship between survival and lymph node assessment from a
population-based study of colorectal cancer patients. (Abstract #6125)
R. Urquhart, J. Bu, G. A. Porter, R. Dewar, R. Moineddin, E. Grunfeld
Brd. 32B Comparison between the causes of rejection to participate (RP) and
screening failures (SF) in oncology clinical trials (OCT). (Abstract #6126)
L. E. Fein, A. Romera, M. C. Micheri, M. I. Diaz, R. A. Sala
Brd. 32C Outcomes from placebo/best supportive care-controlled trials (PBSCT) in the
era of molecular targeted therapy: A meta-analysis. (Abstract #6127)
M. C. Miranda, A. B. Fede, N. Magalhaes, N. Fraile, V. Ayres, M. B. Santos,
S. Gonzaga, K. Brunetti, A. Del Giglio, R. Riechelmann
Brd. 33A Is the informed consent (IC) to treatment truly “informed”? The use of a
comprehension check tool (CCT). (Abstract #6128)
R. Biamonte, S. Turano, C. Mastroianni, V. Liguori, R. De Simone, S. Conforti,
G. Gadaleta-Caldarola, A. Piattelli, M. Iuvaro, S. Palazzo
Brd. 33B Assuring continuous quality improvement using outcomes data: A potential
role for cancer registries. (Abstract #6129)
R. O. Dillman, S. E. McClure
Brd. 33C Evaluation of hormone receptor and benefit from adjuvant chemotherapy
in breast cancer patients with intermediate- and high-risk disease.
(Abstract #6130)
C. Kurzeder, A. Woeckel, T. Kuehn, E. Schlicht, M. Blettner, R. E. Felberbaum,
M. Wischnewsky, R. Kreienberg
Brd. 34A Second-line pancreatic cancer therapy: Patterns of care and survival.
(Abstract #6131)
S. N. Hoang, J. R. Hoverman, B. Turnwald, US Oncology Pathways Task Force
Brd. 34B Effect of race and comorbidities on patterns of bevacizumab toxicity: A
single-institution experience. (Abstract #6132)
M. Raza, S. Raza, Z. Latif, J. C. Sachdev
Brd. 34C Symptom burden in chronic myeloid leukemia (CML). (Abstract #6133)
L. A. Williams, P. Ault, C. S. Cleeland, R. J. Reynolds, N. A. Shah, P. K. Shah,
J. E. Cortes
Brd. 35A Correlation of 5-year survival and cure in NSCLC: An analysis of delayed
cancer deaths in long-term survivors of NSCLC. (Abstract #6134)
M. O. Hubbard, P. Fu, J. L. Worthington, A. Dowlati, P. A. Linden
Brd. 35B Impact of neoadjuvant chemotherapy on breast reconstruction. (Abstract
#6135)
Y. Hu, C. M. Weeks, H. In, C. M. Dodgion, M. Golshan, Y. S. Chun, M. J. Hassett,
X. Gu, S. R. Lipsitz, C. C. Greenberg
Brd. 35C Can patient-reported kidney cancer–specific symptoms at baseline serve as
an indicator for median progression-free and overall survival in sorafenibrefractory
metastatic renal cell carcinoma? (Abstract #6136)
P. C. Trask, A. G. Bushmakin, J. C. Cappelleri, J. C. Tarazi, B. Rosbrook,
P. W. Bycott, S. Kim, W. M. Stadler, B. I. Rini
Brd. 35D Impact of comorbidities on clinical and economic outcomes among patients
with advanced non-small cell lung cancer (NSCLC) receiving care in the
community-based outpatient setting. (Abstract #6137)
J. R. Hoverman, S. K. Gruschkus, C. E. Muehlenbein, M. T. Forsyth, C. Chen,
A. H. Lawson, G. Pohl
375
MONDAY